IMO. far, far too dangerous to be out of ACTC at this crucial time.
I can understand wanting one's dollars working for them as quickly as possible, if you will, but in the case of ACTC, thew vagaries of the general market now notwithstanding, all sorts of potential blockbuster news appears to be a few weeks away and that's everything including, patient leaks of results, announcement of continued clinical trials negating any negatives of safety concerns, major company conference presentations soon, company's previously announced intention to release results and information in october, positive news paving the way for a blockbuster joint venture with a big pharma which could easily negate any need for further consideration of a rs,developments on the human blood initiative, etc., etc. The list is endless and it's all on the near horizon.
THE WHOLE MATTER OF COMMERCIALZATION AND PROFITS WILL BE FACTORED INTO THE PRICE BY THE MARKET LONG BEFORE THE REALITY, ONCE THE POSITIVES NOTED ARE ESTABLISHED, IMO.